letrozole and Dwarfism
letrozole has been researched along with Dwarfism in 4 studies
Dwarfism: A genetic or pathological condition that is characterized by short stature and undersize. Abnormal skeletal growth usually results in an adult who is significantly below the average height.
Research Excerpts
Excerpt | Relevance | Reference |
---|---|---|
" ISS boys with letrozole-induced hypergonadotropic hyperandrogenism had, after 12 months of therapy, higher INSL3 levels than did placebo treated (0." | 5.12 | Serum insulin-like factor 3 levels during puberty in healthy boys and boys with Klinefelter syndrome. ( Andersson, AM; Bay, K; Dunkel, L; Hero, M; Wikström, AM, 2006) |
Research
Studies (4)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (25.00) | 29.6817 |
2010's | 2 (50.00) | 24.3611 |
2020's | 1 (25.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Ma, Y | 1 |
Jia, R | 1 |
Xia, B | 1 |
Tang, B | 1 |
Xu, Z | 1 |
Cui, YP | 1 |
Wang, XL | 1 |
Mauras, N | 1 |
Ross, JL | 1 |
Gagliardi, P | 1 |
Yu, YM | 1 |
Hossain, J | 1 |
Permuy, J | 1 |
Damaso, L | 1 |
Merinbaum, D | 1 |
Singh, RJ | 1 |
Gaete, X | 1 |
Mericq, V | 1 |
Wikström, AM | 1 |
Bay, K | 1 |
Hero, M | 1 |
Andersson, AM | 1 |
Dunkel, L | 1 |
Clinical Trials (1)
Trial Overview
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Randomized Controlled Trial Of The Use Of Aromatase Inhibitors, Alone And In Combination With Growth Hormone In Adolescent Boys With Idiopathic Short Stature[NCT01248416] | Phase 3 | 76 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Change in Body Mass Index
(NCT01248416)
Timeframe: 0 to 24 months
Intervention | kg/m^2 (Mean) |
---|---|
Aromatase Inhibitor | 2.5 |
Growth Hormone | 1.7 |
Aromatase Inhibitor and Growth Hormone | 2.5 |
Change in Bone Density z Score Adjusted for Height
(NCT01248416)
Timeframe: 0 to 24 months
Intervention | z-score (Least Squares Mean) |
---|---|
Aromatase Inhibitor | -1.061 |
Growth Hormone | -0.586 |
Aromatase Inhibitor and Growth Hormone | -0.605 |
Change in Estradiol
Those taking AI alone or AI/GH combined were grouped by type, either anastrozole or letrozole. (NCT01248416)
Timeframe: 0 to 24 months
Intervention | pg/mL (Mean) |
---|---|
Anastrozole | 8 |
Letrozole | 4 |
Change in Estrone
(NCT01248416)
Timeframe: 0 to 24 months
Intervention | pg/mL (Mean) |
---|---|
Aromatase Inhibitor | 0.0 |
Growth Hormone | 6.1 |
Aromatase Inhibitor and Growth Hormone | -0.9 |
Change in Height
Differences in height gains (NCT01248416)
Timeframe: 0 to 24 months
Intervention | Centimeters (Mean) |
---|---|
Aromatase Inhibitor | 14 |
Growth Hormone | 17.1 |
Aromatase Inhibitor and Growth Hormone | 18.9 |
Change in IGF-I Concentrations
(NCT01248416)
Timeframe: 0 to 24 months
Intervention | ng/mL (Mean) |
---|---|
Aromatase Inhibitor | 158 |
Growth Hormone | 280 |
Aromatase Inhibitor and Growth Hormone | 303 |
Change in Lean Body Mass
(NCT01248416)
Timeframe: 0 to 24 months
Intervention | kg (Mean) |
---|---|
Aromatase Inhibitor | 42.2 |
Growth Hormone | 42.0 |
Aromatase Inhibitor and Growth Hormone | 46.5 |
Change in Predicted Height
Primary efficacy end point: change in predicted height (cm) from baseline at 24 months based on change in bone age (years) (NCT01248416)
Timeframe: 0 to 24 months
Intervention | centimeters (Least Squares Mean) |
---|---|
Aromatase Inhibitor | 0.5 |
Growth Hormone | 4.9 |
Aromatase Inhibitor and Growth Hormone | 7.4 |
Change in Testosterone
(NCT01248416)
Timeframe: 0 to 24 months
Intervention | ng/dL (Mean) |
---|---|
Aromatase Inhibitor | 737 |
Growth Hormone | 372 |
Aromatase Inhibitor and Growth Hormone | 668 |
Trials
2 trials available for letrozole and Dwarfism
Article | Year |
---|---|
Randomized Trial of Aromatase Inhibitors, Growth Hormone, or Combination in Pubertal Boys with Idiopathic, Short Stature.
Topics: Adolescent; Anastrozole; Aromatase Inhibitors; Body Composition; Body Height; Drug Therapy, Combinat | 2016 |
Serum insulin-like factor 3 levels during puberty in healthy boys and boys with Klinefelter syndrome.
Topics: Adolescent; Age Determination by Skeleton; Aromatase Inhibitors; Body Height; Child; Dwarfism; Healt | 2006 |
Other Studies
2 other studies available for letrozole and Dwarfism
Article | Year |
---|---|
Adult height in pubertal boys with short stature treated with GH/letrozole: a hospital record-based retrospective study.
Topics: Adult; Dwarfism; Growth Hormone; Hospital Records; Human Growth Hormone; Humans; Letrozole; Male; Re | 2022 |
[Clinical effect of letrozole in treatment of idiopathic short stature in adolescent boys].
Topics: Adolescent; Body Height; Dwarfism; Growth Disorders; Human Growth Hormone; Humans; Letrozole; Male; | 2019 |